David K. Barr concentrates in the areas of patent, trade secret, and unfair competition litigation and counseling. Mr. Barr's experience includes litigation in federal and state courts, appeals to the Federal Circuit Court of Appeals and practice before the US Patent and Trademark Office, including contentious inter partes proceedings. Mr. Barr has been lead trial counsel in many complex Hatch-Waxman and biotech patent infringement cases, and has counseled clients on product development and strategic patent planning. He has extensive experience in intellectual property transactions, including licenses and acquisitions. Mr. Barr has also conducted numerous patent due diligence investigations, and has drafted patent license and related agreements. His patent matters have involved a variety of technologies, including biotechnology, pharmaceuticals, industrial chemistry and biomedical and mechanical devices.

Mr. Barr has authored articles and has lectured on a variety of intellectual property issues. He is a co-author and co-editor of the treatise Pharmaceutical and Biotech Patent Law (Practising Law Institute, 2016).

Mr. Barr received his law degree from the George Washington University Law School, where he was an Associate Editor of the George Washington Journal of International Law and Economics.

Daniel Reisner focuses on patent and trade secret litigation involving biotechnology, pharmaceuticals, ANDA filings, medical devices and telecommunications.

For over two decades Mr. Reisner has worked on numerous trials and has broad experience in all phases of litigation for a variety of clients including Pfizer, Novartis, GSK, Sanofi and Regeneron.  His cases have involved a multitude of therapeutics and devices including Celebrex, Viagra, Gleevec, cardiac monitoring and HCV detection.

Along with David Barr, Mr. Reisner has served as the co-editor and a principal author of Pharmaceutical and Biotech Patent Law.